inosine-diphosphate and Sleep-Wake-Disorders

To analyze the efficacy of cytoflavin in the complex treatment of sleep disorders in asthenic syndrome.. One hundred patients with sleep disorders and asthenic syndrome of various etiology and severity were studied. The patients were divided into three groups depending on the type of therapy: the first group received intravenous infusions of cytoflavin for 10 days; the second group, in addition to cytoflavin, received per os melatonin (3 mg or 5 mg) at bedtime; the third group in addition to cytoflavin received per os zopiclone (7.5 mg) at bedtime.. On the 14th day of the study, a decrease in severity or complete relief of asthenia manifestations (according to the SHAS scale) and, accordingly, improvement or normalization of sleep in 97% of patients was found. At the same time, during polysomnographic study, the data obtained are characteristic for improving the quality of sleep phases mainly in the first and second groups of patients and, to a lesser extent, in the third group.. Cytoflavin effectively suppresses the main manifestations of asthenic syndrome, including sleep disorders.. Цель исследования. Анализ эффективности применения лекарственного препарата (ЛП) Цитофлавин в комплексной коррекции расстройств сна при астеническом синдроме (АС). Материал и методы. Обследовали 100 пациентов с расстройствами сна на фоне АС различной этиологии и степени выраженности. Они были разделены на три группы в зависимости от вида проводимой терапии: 1-й группе больных были назначены внутривенные инфузии ЛП Цитофлавин в течение 10 дней; 2-й группе в дополнение к ЛП Цитофлавин перед сном был назначен per os ЛП Мелатонин (3 или 5 мг); пациенты 3-й группы в дополнение к ЛП Цитофлавин получали перед сном per os ЛП Зопиклон (7,5 мг). Результаты и заключение. На 11-й день исследования было выявлено уменьшение выраженности или полное купирование проявлений астении (по шкале ШАС) и соответственно улучшение или нормализация сна у 97% больных. Вместе с тем при полисомнографическом исследовании получены данные, характерные для улучшения качества фаз сна, преимущественно в 1-й и 2-й группах пациентов и в меньшей степени в 3-й группе. Цитофлавин, являясь нейрометаболическим энергокорректором с антигипоксической и антиоксидантной активностью, эффективно купирует основные проявления АС, в том числе при нарушениях сна.

Topics: Administration, Oral; Antioxidants; Asthenia; Drug Combinations; Flavin Mononucleotide; Humans; Inosine Diphosphate; Melatonin; Niacinamide; Sleep Wake Disorders; Succinates; Syndrome; Treatment Outcome

To evaluate the efficacy of cytoflavin in the treatment of patients with hypertensive encephalopathy (HE).. One hundred and forty patients aged 39 to 73 years, diagnosed with HE, were examined and randomized to 2 groups. A study group (n = 74) received cytoflavin in a dose of 2 tablets b.i.d. on days 1 to 25 days inclusive during standard basic therapy. A comparison group (n = 66 persons) had standard basic therapy only. A control group consisted of 30 apparently healthy individuals. The investigators studied the frequency of headache, dizziness, and other complaints and the intensity of cephalalgic syndrome, by using a visual analog scale, the quality of life by the Medical Outcomes Study 36-Item Short-Form Health Survey (MOS SF-36) questionnaire, that of sleep by the subjective sleep characteristics questionnaire elaborated at the Moscow City Somnological Center, the level of asthenia by a subjective asthenia rating scale (Multidimensional Fatigue Inventory (MFI-20), and autonomic status, by applying objective and subjective scales on days 1 and 25 of therapy.. The study has shown that cytoflavin used in the above dose for 25 days reduces the frequency and magnitude of complaints of headache, dizziness, "venous" complaints, the degree of autonomic and asthenic disorders, and impairments in the quality of sleep and life in the patients with HE at all disease stages. A stepwise discriminant analysis has indicated that the degree of cephalgic syndrome, and autonomic disorders, and worse sleep quality are the most effective points for using the energy-modifier cytoflavin.. HE treatment based on the current pathogenetic principles may have a preventive impact on the development of HE or slow down the rate of its progression.

Topics: Administration, Oral; Adult; Aged; Dose-Response Relationship, Drug; Drug Combinations; Drug Monitoring; Energy Metabolism; Female; Flavin Mononucleotide; Headache; Humans; Hypertensive Encephalopathy; Inosine Diphosphate; Male; Middle Aged; Neurocirculatory Asthenia; Niacinamide; Pain Measurement; Polysomnography; Quality of Life; Severity of Illness Index; Sleep Wake Disorders; Succinates; Treatment Outcome; Visual Analog Scale; Vitamin B Complex